- Co-founded in 2014 as academic spin-out
- First clinical study initiated 2017
- Jane Theaker, Chief Executive Officer since December, 2021
- Actiphage patents published:
- 2015 Mycobacteria Detection using bacteriophages
- 2020 Methods relating to Tuberculosis (the transition from incipient to active infection in LTBI patients)
- Clinical research
- 2020 Actiphage Proof-of-Concept (POC) Leicester 1, published CID
- 2022 Actiphage POC Leicester 2, presented ECCMID 2022
January 19, 2023
PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis (TB) and will be suspending its commercial Johne’s Testing Service.
PBD Biotech is announcing that is focusing its efforts on developing Actiphage as a rapid blood test for Human Tuberculosis...